Company news: Johnson & Johnson, Forest Labs and Berkery Noyes

Share this article:

Johnson & Johnson said sales rose 6.8% in the third quarter vs. the same period last year but that net earnings fell 6.3%. US sales of OTC medicines were down 4.5%, impacted by ongoing quality and manufacturing issues, as were pharmaceutical sales, down 6.1% due to generic competition for antibiotic Levaquin. Outside the US, OTC sales rose 10.1%, and pharmaceutical revenues gained by 27.5%. The company is launching new drugs including prostate cancer med Zytiga and buying device firm Synthes for about $21 billion.

 

Forest Labs said net income fell 12.7% for the three months ended September 30 (its fiscal second quarter), as compared to the same period a year ago. The company launched two new drugs during the quarter, as it seeks to replace revenue to be lost next year from top-selling antidepressant Lexapro's expected patent expiry. These are COPD drug Daliresp, which has posted $1.2 million in sales since debuting in August, and antidepressant Viibryd, which generated $5.3 million in revenue. Revenue for brands Lexapro and Namenda increased 4.7% and 8.6%, respectively

 

According to a report from investment bank Berkery Noyes on mergers and acquisitions among information and technology companies serving pharma and healthcare, transaction value slowed 6% in the third quarter vs. the second. However, transaction value rose 245%. Berkery Noyes attributes this sharp increase to Blackstone Group's announced third-quarter acquisition of medical data services firm Emdeon for $3.03 billion, the largest transaction so far in 2011. The most active acquirer during the quarter was PerkinElmer with four acquisitions: Labtronics, Geospiza, CambridgeSoft and ArtusLabs.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.